Discovery of novel DNA methyltransferase 3A inhibitors via structure-based virtual screening and biological assays. Issue 2 (15th January 2017)

• Record Type: Journal Article
• Authors: Shao, Zhiyuan; Xu, Pan; Xu, Wen; Li, Linjuan; Liu, Shien; Zhang, Rukang; Liu, Yu-Chih; Zhang, Chenhua; Chen, Shijie; Luo, Cheng
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 27:Issue 2(2017)
• Page Start: 342
• Page End: 346
• Publication Date: 2017-01-15
• Subjects: Epigenetics -- DNMT3A inhibitors -- Virtual screening -- Molecular docking; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2016.11.023
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Novel DNMT3A inhibitor 40 was discovered via combining pharmacophore mapping and docking-based virtual screening, with in vitro IC50 of 46.5 μM. Abstract: DNA methyltransferases are involved in diverse biological processes and abnormal methylation patterns play essential roles in cancer initiation and progression. DNA methyltransferase 3A (DNMT3A) acting as a de novo DNA methyltransferase, has gained widespread attention especially in haematological diseases. To date, large numbers of DNMTs inhibitors have been discovered, however, the small molecular inhibitors targeting DNMT3A are still in its infancy. In this study, structure-based virtual screening in combination with biological assays was performed to discovery potent novel DNMT3A inhibitors. Compound 40 and 40_3 displayed comparable in vitro inhibitory activity against DNMT3A with IC50 values of 46.5 μM and 41 μM, respectively. Further binding mode analysis suggested these molecules inhibit DNMT3A activity through binding the S-adenosyl-l -methionine (SAM) pocket. Overall, 40 and 40_3 may serve as novel scaffolds for further optimization and small molecular probes for investigating DNMT3A function.